Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth's Q2 FY2027 revenue rose 22% year over year to $81.4 million, with cannabis revenue up 30% to $66.2 million and international cannabis revenue up 141% to $12.3 million. Adjusted EBITDA loss narrowed to $2.9 million, and management reiterated its expectation of positive adjusted EBITDA in the second half of fiscal 2027; cash and short-term investments totaled $320 million. Results included headwinds: adjusted gross margin fell to 31% from 33%, while net loss widened to $40.7 million, including $35.8 million in fair-value charges related to Canopy USA assets.

Analysis

Investment read-through: The thesis is operational leverage, not simply faster sales. If cultivation changes lift saleable, EU-compliant flower and international demand absorbs it, Canopy can improve utilization and reduce unit costs without expanding the footprint. But management says those benefits arrive mainly in FY28; near-term profitability depends more on seasonality and cost control than on the cultivation upgrade. European growth is also not automatically durable: increased supply from Canadian and other exporters could pressure realized prices, while market access and patient demand remain regulatory- and channel-dependent.

Contrarian view: The growth narrative may overstate organic momentum. MTL contributes to Canadian growth, and international growth is from a smaller base; neither establishes that consolidated margins have turned. The VAC reimbursement change is a structural headwind, while S&B’s consumer exposure makes its seasonal contribution less reliable. Cash provides flexibility, but continuing cash outflow, integration execution, and possible equity issuance keep dilution and capital allocation relevant.

Catalysts / risks: Over the next 1–3 months, watch holiday-quarter S&B performance and sequential adjusted EBITDA. Over 6–18 months, the key test is whether Kincardine output and quality translate into higher cannabis gross margin and whether the Smiths Falls certification produces commercial orders. The article contains material inconsistencies in segment revenue figures between its takeaways and transcript; verify against the filed release before trading on segment-level growth. Thesis weakens if cannabis margins keep falling, EBITDA improvement stalls, or European sales growth fails to convert to cash.

Key Decisions for Investors

• No high-conviction directional trade on this transcript alone. Treat WEED as a catalyst-driven watch; verify segment revenue and reported cash-flow figures against the filing before sizing exposure.
• For existing longs, retain only a risk-sized position into the next quarter and reassess on sequential adjusted EBITDA, cannabis gross margin, and operating cash flow—not revenue growth alone. A reversal in those metrics would invalidate the near-term improvement thesis.
• Potential entry trigger: evidence in the next 1–2 quarters that international growth is accompanied by better cannabis gross margin and lower cash outflow. If those confirm, consider adding WEED; otherwise avoid paying for FY28 yield gains before they appear in results.
• Monitor dilution and execution: renewed ATM issuance, a share consolidation needed to maintain listing, or acquisition spending without measurable synergy progress would worsen the risk/reward.